Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab in EGFR-mutant NSCLC after EGFR TKI failure (China)
CTR20192656Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Roche. Started Jun 2020; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20192656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192656.